Insulin
Endocrinology
Hepatology (Liver, Pancreatic, Gall Bladder)
Nonalcoholic steatohepatitis
Type 1 diabetes mellitus
Type 2 diabetes mellitus
Phase II
Undisclosed
India
Israel
United States
Blank
Highest Development Status: Phase II
Therapeutic Area: Endocrinology
Interventions: Insulin
Product Type: Large molecule
Sponsor: Oramed Ltd.
Receptors: Insulin receptor agonist
Trial ID: NCT01889667
Location: United States
Condition: Type 2 diabetes mellitus
Product Status: Approved
Dosage Form: Capsule
Collaborator: Integrium
Recruitment Status: Completed
Date Of Registration: 19-06-2013
Product Description: ORMD-0801 (Oral Insulin) has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment.
Expand
Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, PK and PD of Multiple O...
Product Description: ORMD-0801 (Oral Insulin) has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment.
Product Status: Approved
Dosage Form: Capsule
Collapse
Highest Development Status: Phase II
Therapeutic Area: Endocrinology
Interventions: Insulin
Location: United States
Condition: Type 2 diabetes mellitus
Product Type: Large molecule
Sponsor: Oramed Ltd.
Receptors: Insulin receptor agonist
Trial ID: NCT01889667
Product Description: ORMD-0801 (Oral Insulin) has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment.
Product Status: Approved
Dosage Form: Capsule
Collaborator: Integrium
Recruitment Status: Completed
Date Of Registration: 19-06-2013
Highest Development Status: Phase II
Therapeutic Area: Endocrinology
Interventions: Insulin
Product Type: Large molecule
Sponsor: Oramed Ltd.
Receptors: Insulin receptor agonist
Trial ID: NCT02094534
Location: United States
Condition: Type 1 diabetes mellitus
Product Status: Approved
Dosage Form: Capsule
Collaborator: Integrium
Recruitment Status: Completed
Date Of Registration: 20-03-2014
Product Description: ORMD-0801 (Oral Insulin) capsule has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment.
Expand
A Prospective, Randomized, Double-blind, Placebo Controlled Study to Assess the Impact of ORMD-0...
Product Description: ORMD-0801 (Oral Insulin) capsule has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment.
Product Status: Approved
Dosage Form: Capsule
Collapse
Highest Development Status: Phase II
Therapeutic Area: Endocrinology
Interventions: Insulin
Location: United States
Condition: Type 1 diabetes mellitus
Product Type: Large molecule
Sponsor: Oramed Ltd.
Receptors: Insulin receptor agonist
Trial ID: NCT02094534
Product Description: ORMD-0801 (Oral Insulin) capsule has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment.
Product Status: Approved
Dosage Form: Capsule
Collaborator: Integrium
Recruitment Status: Completed
Date Of Registration: 20-03-2014
Highest Development Status: Phase II
Therapeutic Area: Endocrinology
Interventions: Insulin
Product Type: Large molecule
Sponsor: Oramed Ltd.
Receptors: Insulin receptor agonist
Trial ID: NCT02496000
Location: United States
Condition: Type 2 diabetes mellitus
Product Status: Approved
Dosage Form: Capsule
Collaborator: Integrium
Recruitment Status: Completed
Date Of Registration: 08-07-2015
Product Description: ORMD-0801 (Oral Insulin) capsule has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment.
Expand
Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Multiple...
Product Description: ORMD-0801 (Oral Insulin) capsule has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment.
Product Status: Approved
Dosage Form: Capsule
Collapse
Highest Development Status: Phase II
Therapeutic Area: Endocrinology
Interventions: Insulin
Location: United States
Condition: Type 2 diabetes mellitus
Product Type: Large molecule
Sponsor: Oramed Ltd.
Receptors: Insulin receptor agonist
Trial ID: NCT02496000
Product Description: ORMD-0801 (Oral Insulin) capsule has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment.
Product Status: Approved
Dosage Form: Capsule
Collaborator: Integrium
Recruitment Status: Completed
Date Of Registration: 08-07-2015
Highest Development Status: Phase II
Therapeutic Area: Endocrinology
Interventions: Insulin
Product Type: Large molecule
Sponsor: Oramed Ltd.
Receptors: Insulin receptor agonist
Trial ID: NCT02954601
Location: United States
Condition: Type 2 diabetes mellitus
Product Status: Approved
Dosage Form: Capsule
Collaborator: Integrium
Recruitment Status: Completed
Date Of Registration: 13-10-2016
Product Description: ORMD-0801 (Oral Insulin) capsule has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment.
Expand
A Phase 2a, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, 3-Way Crossover Study to...
Product Description: ORMD-0801 (Oral Insulin) capsule has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment.
Product Status: Approved
Dosage Form: Capsule
Collapse
Highest Development Status: Phase II
Therapeutic Area: Endocrinology
Interventions: Insulin
Location: United States
Condition: Type 2 diabetes mellitus
Product Type: Large molecule
Sponsor: Oramed Ltd.
Receptors: Insulin receptor agonist
Trial ID: NCT02954601
Product Description: ORMD-0801 (Oral Insulin) capsule has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment.
Product Status: Approved
Dosage Form: Capsule
Collaborator: Integrium
Recruitment Status: Completed
Date Of Registration: 13-10-2016
Highest Development Status: Phase II
Therapeutic Area: Endocrinology
Interventions: Insulin
Product Type: Large molecule
Sponsor: The University of Texas Health Science C...
Receptors: Insulin receptor agonist
Trial ID: NCT02535715
Location: United States
Condition: Type 1 diabetes mellitus
Product Status: Approved
Dosage Form: Capsule
Collaborator: Oramed Ltd.
Recruitment Status: Completed
Date Of Registration: 12-08-2015
Product Description: ORMD-0801 (Oral Insulin) capsule has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment.
Expand
A Euglycemic Insulin Clamp Study in Type 1 Diabetic Patients With Oral Insulin (ORAMED)
Product Description: ORMD-0801 (Oral Insulin) capsule has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment.
Product Status: Approved
Dosage Form: Capsule
Collapse
Highest Development Status: Phase II
Therapeutic Area: Endocrinology
Interventions: Insulin
Location: United States
Condition: Type 1 diabetes mellitus
Product Type: Large molecule
Sponsor: The University of Texas Health Science C...
Receptors: Insulin receptor agonist
Trial ID: NCT02535715
A Euglycemic Insulin Clamp Study in Type 1 Diabetic Patients With Oral Insulin (ORAMED)
Product Description: ORMD-0801 (Oral Insulin) capsule has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment.
Product Status: Approved
Dosage Form: Capsule
Collaborator: Oramed Ltd.
Recruitment Status: Completed
Date Of Registration: 12-08-2015
Highest Development Status: Phase II
Therapeutic Area: Hepatology (Liver, Pancreatic,...
Interventions: Insulin
Product Type: Large molecule
Sponsor: Oramed Ltd.
Receptors: Insulin receptor agonist
Trial ID: NCT02653300
Location: Israel
Condition: Nonalcoholic steatohepatitis
Product Status: Approved
Dosage Form: Soft gel capsule
Collaborator: Hadassah Medical Organ...
Recruitment Status: Recruiting
Date Of Registration: 24-12-2015
Product Description: ORMD-0801 (Oral Insulin) capsule has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment.
Expand
Highest Development Status: Phase II
Therapeutic Area: Hepatology (Liver, Pancreatic,...
Interventions: Insulin
An Open-Label Pilot Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Potential...
Product Description: ORMD-0801 (Oral Insulin) capsule has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment.
Product Status: Approved
Dosage Form: Soft gel capsule
Collapse
Highest Development Status: Phase II
Therapeutic Area: Hepatology (Liver, Pancreatic,...
Interventions: Insulin
Location: Israel
Condition: Nonalcoholic steatohepatitis
Product Type: Large molecule
Sponsor: Oramed Ltd.
Receptors: Insulin receptor agonist
Trial ID: NCT02653300
Product Description: ORMD-0801 (Oral Insulin) capsule has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment.
Product Status: Approved
Dosage Form: Soft gel capsule
Collaborator: Hadassah Medical Organ...
Recruitment Status: Recruiting
Date Of Registration: 24-12-2015
Highest Development Status: Phase II
Therapeutic Area: Endocrinology
Interventions: Insulin
Product Type: Large molecule
Sponsor: Oramed Ltd.
Receptors: Insulin receptor agonist
Trial ID: NCT04150107
Location: United States
Condition: Type 1 diabetes mellitus
Product Status: Approved
Dosage Form: Capsule
Collaborator: Integrium
Recruitment Status: Recruiting
Date Of Registration: 31-10-2019
Product Description: ORMD-0801 (Oral Insulin) capsule has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment.
Expand
A Phase 2 Randomized, Open Label Crossover Study to Compare ORMD-0801 Given Once Daily at Bedtim...
Product Description: ORMD-0801 (Oral Insulin) capsule has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment.
Product Status: Approved
Dosage Form: Capsule
Collapse
Highest Development Status: Phase II
Therapeutic Area: Endocrinology
Interventions: Insulin
Location: United States
Condition: Type 1 diabetes mellitus
Product Type: Large molecule
Sponsor: Oramed Ltd.
Receptors: Insulin receptor agonist
Trial ID: NCT04150107
Product Description: ORMD-0801 (Oral Insulin) capsule has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment.
Product Status: Approved
Dosage Form: Capsule
Collaborator: Integrium
Recruitment Status: Recruiting
Date Of Registration: 31-10-2019
Highest Development Status: Phase II
Therapeutic Area: Endocrinology
Interventions: Insulin
Product Type: Large molecule
Sponsor: Oramed Ltd.
Receptors: Insulin receptor agonist
Trial ID: NCT03467932
Location: United States
Condition: Type 2 diabetes mellitus
Product Status: Approved
Dosage Form: Capsule
Collaborator: Integrium
Recruitment Status: Completed
Date Of Registration: 01-03-2018
Product Description: ORMD-0801 (Oral Insulin) capsule has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment.
Expand
A Placebo-controlled, Multi-center, Randomized, Phase 2b Study to Evaluate the Efficacy and Safe...
Product Description: ORMD-0801 (Oral Insulin) capsule has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment.
Product Status: Approved
Dosage Form: Capsule
Collapse
Highest Development Status: Phase II
Therapeutic Area: Endocrinology
Interventions: Insulin
Location: United States
Condition: Type 2 diabetes mellitus
Product Type: Large molecule
Sponsor: Oramed Ltd.
Receptors: Insulin receptor agonist
Trial ID: NCT03467932
Product Description: ORMD-0801 (Oral Insulin) capsule has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment.
Product Status: Approved
Dosage Form: Capsule
Collaborator: Integrium
Recruitment Status: Completed
Date Of Registration: 01-03-2018
Highest Development Status: Phase II
Therapeutic Area: Endocrinology
Interventions: Insulin
Product Type: Large molecule
Sponsor: Oramed Inc
Receptors: Insulin receptor agonist
Trial ID: CTRI/2009/091/000371
Location: India
Condition: Type 2 diabetes mellitus
Product Status: Approved
Dosage Form: Capsule
Collaborator: Integrium
Recruitment Status: Recruiting
Date Of Registration: 10-07-2009
Product Description: ORMD-0801 (Oral Insulin) capsule has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment.
Expand
A Phase 2b, comparative, two arm randomized, placebo-controlled, double blinded multi-centric st...
Product Description: ORMD-0801 (Oral Insulin) capsule has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment.
Product Status: Approved
Dosage Form: Capsule
Collapse
Highest Development Status: Phase II
Therapeutic Area: Endocrinology
Interventions: Insulin
Location: India
Condition: Type 2 diabetes mellitus
Product Type: Large molecule
Sponsor: Oramed Inc
Receptors: Insulin receptor agonist
Trial ID: CTRI/2009/091/000371
Product Description: ORMD-0801 (Oral Insulin) capsule has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment.
Product Status: Approved
Dosage Form: Capsule
Collaborator: Integrium
Recruitment Status: Recruiting
Date Of Registration: 10-07-2009
Highest Development Status: Phase II
Therapeutic Area: Endocrinology
Interventions: Insulin
Product Type: Large molecule
Sponsor: Hadassah Medical Organization
Receptors: Insulin receptor agonist
Trial ID: NCT00867594
Location: Israel
Condition: Type 1 diabetes mellitus
Product Status: Approved
Dosage Form: Capsule
Collaborator: Oramed Ltd.
Recruitment Status: Completed
Date Of Registration: 22-03-2009
Product Description: ORMD-0801 (Oral Insulin) capsule has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment.
Expand
Effectiveness of Oral Insulin in Unstable Type 1 Diabetes Patients
Product Description: ORMD-0801 (Oral Insulin) capsule has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment.
Product Status: Approved
Dosage Form: Capsule
Collapse
Highest Development Status: Phase II
Therapeutic Area: Endocrinology
Interventions: Insulin
Location: Israel
Condition: Type 1 diabetes mellitus
Product Type: Large molecule
Sponsor: Hadassah Medical Organization
Receptors: Insulin receptor agonist
Trial ID: NCT00867594
Effectiveness of Oral Insulin in Unstable Type 1 Diabetes Patients
Product Description: ORMD-0801 (Oral Insulin) capsule has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment.
Product Status: Approved
Dosage Form: Capsule
Collaborator: Oramed Ltd.
Recruitment Status: Completed
Date Of Registration: 22-03-2009
Highest Development Status: Undisclosed
Therapeutic Area: Endocrinology
Interventions: Exenatide,Insulin
Product Type: Large molecule
Sponsor: Oramed Inc
Receptors: Insulin receptor agonist||Gluc...
Trial ID: NA
Location: NA
Condition: Type 2 diabetes mellitus
Product Status: Approved
Dosage Form: Oral
Collaborator: NA
Recruitment Status: NA
Date Of Registration: NA
Product Description: ORMD-0801 (Oral Insulin) capsule and ORMD-0901 (Exenatide), a GLP-1 analog are pursuing an oral combination therapy for the management of T2DM without an increased risk for hypoglycemia.
Expand
Highest Development Status: Undisclosed
Therapeutic Area: Endocrinology
Oral Combination Therapy for the Management of T2DM, by Combining the Advantages of ORMD-0801 an...
Product Description: ORMD-0801 (Oral Insulin) capsule and ORMD-0901 (Exenatide), a GLP-1 analog are pursuing an oral combination therapy for the management of T2DM without an increased risk for hypoglycemia.
Product Status: Approved
Dosage Form: Oral
Collapse
Highest Development Status: Undisclosed
Therapeutic Area: Endocrinology
Interventions: Exenatide,Insulin
Location: NA
Condition: Type 2 diabetes mellitus
Product Type: Large molecule
Sponsor: Oramed Inc
Receptors: Insulin receptor agonist||Gluc...
Trial ID: NA
Product Description: ORMD-0801 (Oral Insulin) capsule and ORMD-0901 (Exenatide), a GLP-1 analog are pursuing an oral combination therapy for the management of T2DM without an increased risk for hypoglycemia.
Product Status: Approved
Dosage Form: Oral
Collaborator: NA
Recruitment Status: NA
Date Of Registration: NA
PharmaCompass >>
Market Place
